Objective: Gonadotropin-releasing hormone agonists (GnRHa) are the treatment of choice for CPP and have been widely used for decades. We assessed to determine the effect of gonadotropin-releasing hormone agonist (GnRHa) treatment on auxological outcome of girls with idiopathic central precocious puberty (CPP). Methods: This study included 96 girls treated with depot leuprolide acetate monthly who reached adult height. The final adult height (FAH) was compared with midparental height (MPH) and initial predicted adult height ( PAH). Also, multivariate analysis of the factors associated with FAH was performed in all girls with CPP. Results: The final evaluation was carried out at a mean age of 14.0 ± 0.8 years after mean treatment duration of 2.93 ± 0.72 years. Menarche appeared at 16.8 ± 5.8 months (range, 6 –38 months) after discontinuing GnRHa treatment. FAH was 159.9 ± 5.0 cm, which was significantly higher that initial PAH (156.1 ± 5.7 cm) ( P0.001) and it was similar to the MPH (159.1 ± 3.8 cm). FAH was significantly and positively associated with height SDS at the start, MPH, and treatment duration. Conclusion: FAH was significantly higher than initial PAH in girls with CPP who were treated with GnRHa. The factors determining FAH were initial height, MPH, and treatment duration.